PRIM, S.A. (0FP0) AI Stock Analysis

PRIM, S.A.

(LSE:0FP0)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Debt-free balance sheetBeing effectively unlevered provides durable financial flexibility: lower interest burden, more optionality for capex, dividends or bolt-on M&A, and greater resilience to cyclical shocks. Over the next 2–6 months this supports stable operations and strategic optionality.

Negative Factors

Uneven cash generationIntermittent negative operating and free cash flow in prior years plus a 2025 FCF step-down versus 2024 signal that cash conversion is inconsistent. This reduces the reliability of internally funded growth and increases sensitivity to working-capital swings and capex over the medium term.

PRIM, S.A. (0FP0) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: EUR 210.17M
Dividend Yield: 4.06%
Average Volume (3M): 1
Price to Earnings (P/E): 16.3
Beta (1Y): 0.42
Revenue Growth: 4.20%
EPS Growth: -10.44%
Country: UK
Employees: 959
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Instruments & Supplies

PRIM, S.A. Business Overview & Revenue Model

Company Description

Prim, S.A., operating through its various affiliated entities, specializes in the conception, production, and sale of orthopedic solutions. These items are utilized across diverse fields such as physical therapy, aquatic therapies (like thalassothera...

PRIM, S.A. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

GB:0FP0 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ES:PHM	65Neutral	EUR 1.20B	20.69	23.64%	1.48%	15.52%	34.76%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ES:ATRY	47Neutral	EUR 198.30M	-2.03	-65.08%	―	-53.44%	-296.14%
ES:ORY	45Neutral	EUR 198.99M	-77.82	-2.23%	―	―	53.50%

* Healthcare Sector Average

Performance Comparison

GB:0FP0 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:0FP0	PRIM, S.A.	12.55	-0.71	-5.38%
ES:ORY	Oryzon Genomics	2.43	-1.07	-30.63%
ES:PHM	Pharma Mar SA	67.50	-4.57	-6.34%
ES:ATRY	Atrys Health SA	2.61	-0.63	-19.44%
ES:LAB	Labiana Health SA	5.20	0.88	20.48%
ES:STNA	Santa Ana Global Enterprises SA	15.40	1.80	13.24%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

PRIM, S.A. AI Stock Analysis